PLA2G12B

Across TCGA pan-cancer cohorts, PLA2G12B RNA differs between tumor and matched normal tissue in 9 of 18 cancer types tested, making tumor–normal expression one of PLA2G12B’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where PLA2G12B RNA is more highly expressed in tumor relative to normal tissue. In most cancer types PLA2G12B is over-expressed in tumor, although a few such as KIRP and LUSC show the opposite, repressed pattern.

THCA, KIRP, and LUSC are the cancer types where PLA2G12B tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PLA2G12B RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	Male	All	+2.356	<.001	10	view →
KIRP	All	III,IV	−2.663	<.001	9	view →
LUSC	All	III,IV	−2.591	<.001	8	view →
KICH	All	II,III,IV	−2.222	<.001	7	view →
KIRC	Male	II,III,IV	+1.846	<.001	7	view →
LUAD	Female	II,III,IV	−1.587	<.001	6	view →
CHOL	Female	All	−5.990	<.001	5	view →
LIHC	All	III,IV	+0.705	.001	3	view →
BRCA	All	III,IV	−0.043	.011	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 9 strongest of 9 lineages.

PLA2G12B–THCA

Open the THCA breakdown →